Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma [Phase 4]
A Phase 4 randomized trial comparing evening dosing of Xalacom versus Cosopt in glaucoma patients completed.
-
FDA approval · 2021-02-10FDA Approved: DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALETAE — Supplemental Application (Indoco Remedies Limited)
FDA approved Indoco Remedies Limited's supplemental application for a generic dorzolamide hydrochloride and timolol maleate ophthalmic solut…
-
CLINICAL_TRIALS trial_result · 2021-02-08Clinical Trial Update: Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost [Phase 4]
Phase 4 trial comparing efficacy and ocular surface outcomes between Monoprost and BAK-preserved latanoprost in glaucoma and ocular hyperten…
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia [Phase 3]
Phase 3 trial update for open angle glaucoma or ocular hypertension conducted in Scandinavia; study completed.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom [Phase 3]
Phase 3 clinical trial in the United Kingdom evaluating treatment for open angle glaucoma or ocular hypertension; study status completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2021-02-02Clinical Trial Update: Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device [Phase 3]
Phase 3 trial evaluating safety and efficacy of Xalatan delivered by a conventional dropper bottle versus a delivery device was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US [Phase 4]
A phase 4 trial comparing latanoprost with travoprost and bimatoprost in patients with elevated intraocular pressure, completed in the US.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension [Phase 2]
A Phase 2 trial comparing latanoprost formulations to Xalatan for primary open-angle glaucoma and ocular hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma [Phase 4]
Phase 4 trial assessing 3 months of latanoprost to reduce intraocular pressure in ocular hypertension or open-angle glaucoma has completed.
-
FDA approval · 2020-12-21FDA Approved: XELPROS — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for XELPROS (latanoprost) by Sun Pharmaceutical Industries, expanding the product’s labeling.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension [Phase 1, Phase 2]
A clinical trial update comparing RKI983 at 0.05% and 0.10% to Xalatan in patients with primary open-angle glaucoma or ocular hypertension; …
-
CLINICAL_TRIALS trial_result · 2020-12-04Clinical Trial Update: Tafluprost Preservative Free Switch Study [Phase 4]
Phase 4 trial update on a tafluprost preservative-free switch study for glaucoma patients.
-
CLINICAL_TRIALS trial_result · 2020-12-01Clinical Trial Update: Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension [Phase 4]
Phase 4 trial comparing generic travoprost to brand-name travoprost in primary open-angle glaucoma or ocular hypertension; results posted af…
-
CLINICAL_TRIALS trial_result · 2020-12-01Clinical Trial Update: Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial [Phase 4]
Phase 4 randomized trial comparing BRIDIN-T 0.15% eye drops to ALPHAGAN-P 0.15% eye drops for efficacy and ocular surface disease in glaucom…
-
CLINICAL_TRIALS trial_result · 2020-11-27Clinical Trial Update: Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension [NA]
Completed clinical trial examining how alternate therapies affect intraocular pressure in ocular hypertension; results posted in 2020.
-
FDA approval · 2020-11-23FDA Approved: COSOPT — Supplemental Application (Thea Pharma Inc.)
The FDA approved a supplemental application for COSOPT, the dorzolamide hydrochloride and timolol maleate combination, submitted by Thea Pha…
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma [NA]
Clinical trial comparing 180-degree versus 360-degree selective laser trabeculoplasty as initial therapy for glaucoma has completed with res…
-
CLINICAL_TRIALS trial_result · 2020-11-04Clinical Trial Update: SYL040012, Treatment for Open Angle Glaucoma [Phase 2]
Phase 2 trial update for SYL040012 in open angle glaucoma and ocular hypertension has completed with results posted.
-
FDA approval · 2020-11-03FDA Approved: DURYSTA — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Durysta (bimatoprost) submitted by Allergan, Inc. This marks approval of an add-on to the ND…
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study [Phase 2]
Phase IIb study of DE-126 ophthalmic solution in open-angle glaucoma or ocular hypertension completed with posted results.
-
FDA approval · 2020-10-22FDA Approved: TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION, 0.25% — Original Application (Alembic Pharmaceuticals Inc.)
Alembic Pharmaceuticals received FDA approval for timolol maleate ophthalmic gel-forming solution in 0.25% (and 0.5%) strengths via original…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan [Phase 2]
Phase 2 trial evaluating the efficacy and systemic safety of netarsudil at 0.01%, 0.02%, and 0.04% versus placebo in open-angle glaucoma or …
-
FDA approval · 2020-09-29FDA Approved: LUMIGAN — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for LUMIGAN (bimatoprost) from Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2020-09-29Clinical Trial Update: Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting [Phase 4]
Phase 4 real-world study of Rhopressa for reducing elevated intraocular pressure in glaucoma or ocular hypertension completed with posted re…
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients [NA]
Clinical trial update on optic nerve head pressure patterns in ocular hypertensive patients who converted to glaucoma versus those remaining…